Linden is a Senior Portfolio Manager at Candriam, managing biotechnology and oncology strategies since 2024.
Prior to joining Candriam, she was the lead manager of a biotech fund at AXA IM as well as the head of their healthcare franchise and a member of the UK Executive Committee. She brings over two decades of buy-side and sell-side experience in biotechnology. Linden started her career at Goldman Sachs in 2003, establishing technical expertise in healthcare, before moving on to a biotech hedge fund at start-up stage and subsequently to AXA Investment Managers in 2011.
Linden holds a BS (Hons) in Medical Microbiology from the University of Edinburgh. She has been a CFA Charterholder since 2011.
